RxDoctor Payments Data

James Persing, MD

Psychiatry · Menomonie, WINPI 1588602379

Payments from drug & device makers

$1,122in general payments, 2019–2025

Across 56 payments — averaging $20.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Neurocrine Biosciences, Inc.$397
  • Otsuka America Pharmaceutical, Inc.$279
  • Teva Pharmaceuticals USA, Inc.$203
  • Lundbeck LLC$84
  • Alkermes, Inc.$46
  • Brainsway USA Inc$44
  • plus $69 from 3 others

What the payments were for

  • Food & beverage$1,01991%
  • Education$1039%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,122 in reported general payments places this provider in the 80th percentile of 543 psychiatry providers in Wisconsin.

See all psychiatry providers in Wisconsin

Medicare billing

Part B allowed, 2024
$38,817
Medicare patients
178
Services billed
974

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate38$342,170
Invega TrinzaPaliperidone Palmitate13$112,519
Abilify MaintenaAripiprazole35$97,232
Risperdal ConstaRisperidone Microspheres26$64,747
VraylarCariprazine Hcl47$64,592
Invega SustennaPaliperidone Palmitate14$45,348
Chlorpromazine Hcl164$41,838
RexultiBrexpiprazole33$35,085
BelsomraSuvorexant51$29,544
Lurasidone Hcl60$24,813
Clozapine OdtClozapine26$21,958
LybalviOlanzapine/Samidorphan Malate12$18,157
Clozapine223$16,535
Haloperidol359$15,133
Olanzapine477$14,187

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$397$342,17038 claims
Johnson & JohnsonInvega Trinza, Risperdal Consta, Invega Sustenna, Invega$11$230,14564 claims
Otsuka America Pharmaceutical, Inc.Abilify Maintena, Rexulti$279$132,31668 claims
AbbVieVraylar, Fetzima$32$70,53259 claims
Alkermes, Inc.Lybalvi$46$18,15712 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 543 psychiatry providers in Wisconsin.

Other psychiatry in Menomonie

See the full list for Wisconsin

Where these figures come from

Is this you, or does something look wrong? →